We traveled to NewYork City, New York, for a State of the Science Summit™ on Breast Cancer, which focused on the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.
We recently traveled to New York City for a State of the Science Summit™ on Breast Cancer. During the meeting, faculty from the Icahn School of Medicine of Mount Sinai Health System, as well as Columbia University Medical Center, discussed the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
2 Commerce Drive
Cranbury, NJ 08512